Renalytix Statistics
Total Valuation
Renalytix has a market cap or net worth of 19.73 million. The enterprise value is 23.69 million.
Market Cap | 19.73M |
Enterprise Value | 23.69M |
Important Dates
The last earnings date was Thursday, October 10, 2024.
Earnings Date | Oct 10, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Shares Outstanding | n/a |
Shares Change (YoY) | +31.59% |
Shares Change (QoQ) | +41.48% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 155.36M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.71 |
EV / Sales | 10.07 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.79 |
Financial Position
The company has a current ratio of 0.53
Current Ratio | 0.53 |
Quick Ratio | 0.47 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -0.28 |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -93.54% |
Return on Capital (ROIC) | -182.66% |
Revenue Per Employee | 22,441 |
Profits Per Employee | -328,000 |
Employee Count | 102 |
Asset Turnover | 0.12 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.17% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -86.17% |
50-Day Moving Average | 0.25 |
200-Day Moving Average | 0.50 |
Relative Strength Index (RSI) | 31.61 |
Average Volume (20 Days) | 357,825 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Renalytix had revenue of 2.29 million and -33.46 million in losses. Loss per share was -0.31.
Revenue | 2.29M |
Gross Profit | 156,000 |
Operating Income | -28.89M |
Pretax Income | -33.45M |
Net Income | -33.46M |
EBITDA | -28.62M |
EBIT | -28.89M |
Loss Per Share | -0.31 |
Balance Sheet
The company has 4.68 million in cash and 8.54 million in debt, giving a net cash position of -3.86 million.
Cash & Cash Equivalents | 4.68M |
Total Debt | 8.54M |
Net Cash | -3.86M |
Net Cash Per Share | n/a |
Equity (Book Value) | -7.85M |
Book Value Per Share | -0.05 |
Working Capital | -5.38M |
Cash Flow
In the last 12 months, operating cash flow was -30.11 million and capital expenditures -4,000, giving a free cash flow of -30.12 million.
Operating Cash Flow | -30.11M |
Capital Expenditures | -4,000 |
Free Cash Flow | -30.12M |
FCF Per Share | n/a |
Margins
Gross Margin | 6.82% |
Operating Margin | -1,261.90% |
Pretax Margin | -1,461.42% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -1,315.64% |
Dividends & Yields
Renalytix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -31.59% |
Shareholder Yield | -31.59% |
Earnings Yield | -206.67% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Renalytix has an Altman Z-Score of -47.39. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -47.39 |
Piotroski F-Score | n/a |